Anthrax is one of the most severe bacterial infections known — the form inhaled through the lungs has historically had mortality rates above 80% even with treatment. It is considered a biological threat agent partly because the toxins it produces directly disable the immune cells that would normally fight it. Researchers have therefore been interested in whether taking certain supplements before potential exposure could put the immune system in a stronger starting position.
A peer-reviewed study published in the Journal of the American Nutraceutical Association investigated whether oral yeast beta-1,3-glucan — the same immune-active compound found in wild mushrooms like Apán — could protect against anthrax in a controlled animal study. Animals given oral beta-glucan before anthrax exposure had significantly better survival than untreated controls. The researchers identified three specific immune signaling proteins as the mechanism: IL-2, IFN-gamma, and TNF-alpha. These three compounds are central to activating and sustaining both the rapid-response and learned branches of the immune system.
What makes this finding notable is how beta-glucan activates these pathways. When you take it orally, immune cells in your gut lining absorb the beta-glucan particles directly. These cells then send activation signals throughout the immune system — essentially raising the baseline readiness of your immune defenses. The anthrax toxin works by disabling the very immune cells that would normally sound the alarm. By having those cells already partially activated, the body's response is faster and more robust than it would be from a standing start.
The study is also compelling because of what anthrax toxin specifically does: it directly attacks the cellular machinery of immune cells, making them unable to respond normally. A supplement that demonstrably elevates the immune system's readiness before that attack has clear logic — the immune system is less vulnerable when it is already mobilized. The data showed this translated into meaningfully better survival outcomes.
Perhaps most remarkable: the same study, using the same animals and the same oral beta-glucan regimen, also found that metastatic cancer cell growth was inhibited. The same three cytokines — IL-2, IFN-gamma, TNF-alpha — appear to be doing the work in both cases. This suggests that beta-glucan is not specifically an anthrax treatment or specifically a cancer treatment, but a broad immune preparedness enhancer that helps the immune system perform better against serious challenges. The researchers called these results promising preclinical evidence and encouraged further study.
